A Phase 1 interventional study of Belimumab in Systemic Lupus Erythematosus, sponsored by GlaxoSmithKline. Completed at 2 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-03-27.
Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies testing belimumab in Lupus Erythematosus, Systemic — 4 open to participants now, 7 under way, none of them phase 3. belimumab · Lupus Erythematosus, Systemic.
Among the 36 studies testing belimumab in Lupus Erythematosus, Systemic, this one is the 30th largest by enrollment, is the only one that started in 2017, is one of 7 in phase 1, and was the 23rd registered.
1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.
Browse Lupus Erythematosus, Systemic studies →4 of the 36 studies testing belimumab in Lupus Erythematosus, Systemic are open now, in 3 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
Nanjing University School of Medicine · Sites in China
Ages 14–65
National University Hospital, Singapore · Sites in Singapore
Ages 21–70
First Affiliated Hospital Xi'an Jiaotong University
Ages 18+
By country, each count listing its studies:
belimumab: first FDA approval 2011 (BENLYSTA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 1 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 20 is below the median of 52 across 878 interventional studies indexed under Lupus Erythematosus, Systemic.
Median enrollment 81 across the 36 interventional studies. Of the 27 that completed or were terminated, 20 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 36 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
43 studies in Lupus Erythematosus, Systemic by GlaxoSmithKline: 1 open now, 4 under way, none of them phase 3. Of 36 finished, 26 (72%) have results posted.
Among the 43 studies in Lupus Erythematosus, Systemic by GlaxoSmithKline, this one is the 31st largest by enrollment of the 36 interventional ones that give a count, is the only one that started in 2017, is one of 14 in phase 1, and was the 30th registered.
GlaxoSmithKline’s Lupus Erythematosus, Systemic studies by the year they started, since 2002.
2 of the studies testing belimumab in Lupus Erythematosus, Systemic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07340463Nanjing University School of MedicineThe Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis Patients for 6 Months Compared With Mycophenolate Mofetil Treatment | 2027-06 |
| NCT06411249GlaxoSmithKlineA Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE) | 2027-06-29 |
Add all 2 to your calendar (.ics) → With an account.
Among the 36 studies testing belimumab in Lupus Erythematosus, Systemic, from their registry updates:
Among GlaxoSmithKline’s 43 in Lupus Erythematosus, Systemic:
This tab as a report to print or save as PDF → With an account.
In China, Belimumab (GSK1550188) will be developed for a dosing regimen of once-monthly intravenous (IV) infusion for the treatment of SLE. This open-label, single dose study will evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of belimumab in Chinese SLE subjects. A total of approximately 20 subjects will be enrolled to receive IV infusion of 10 milligrams per kilogram (mg/kg) GSK1550188 on Day 0 for the treatment of SLE. Subjects will be followed for 84 days after the administration of drug.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In this open label study, a single dose of 10 mg/kg Belimumab will be administered intravenously in Chinese subjects with systemic lupus erythematosus.
Drug: Belimumab
Belimumab will be provided as white uniform lyophilized cake in vials with unit dose strength of 400 mg/vial plus excipients (citric acid/sodium citrate/sucrose/polysorbate) for reconstitution in 4.8 milliliter sterile water for injection (SWFI). Belimumab will be administered as 10 mg/kg intravenous infusion for over 1 hour on Day 0.
Maximum Observed Concentration (Cmax) of Belimumab
Blood samples were collected at the indicated timepoints to calculate Cmax of belimumab.
Time frame: Day 0 (pre-dose, 5 minutes, 1 hour, 6 hours, 24 hours), and on Days 1, 7, 14, 21, 28, 42, 56, and 84 post-dose
Area Under the Concentration-time Curve From Time Zero (Pre-dose) to Last Time of Quantifiable Concentration (AUC [0 to t]) and Area Under the Concentration-time Curve From Time Zero (Pre-dose) Extrapolated to Infinite Time (AUC [0 to Inf]) of Belimumab
Blood samples were collected at the indicated timepoints to calculate AUC (0 to t) and AUC (0 to inf) of belimumab.
Time frame: Day 0 (pre-dose, 5 minutes, 1 hour, 6 hours, 24 hours), and on Days 1, 7, 14, 21, 28, 42, 56, and 84 post-dose
Terminal Phase Half-life (t1/2) of Belimumab
Blood samples were collected at the indicated time points to calculate t1/2 of belimumab.
Time frame: Day 0 (pre-dose, 5 minutes, 1 hour, 6 hours, 24 hours), and on Days 1, 7, 14, 21, 28, 42, 56, and 84 post-dose
Terminal Phase Rate Constant (Lambda z) of Belimumab
Blood samples were collected at the indicated time points to calculate lambda z of belimumab.
Time frame: Day 0 (pre-dose, 5 minutes, 1 hour, 6 hours, 24 hours), and on Days 1, 7, 14, 21, 28, 42, 56, and 84 post-dose
Systemic Clearance (CL) of Belimumab
Blood samples were collected at the indicated time points to calculate CL of belimumab.
Time frame: Day 0 (pre-dose, 5 minutes, 1 hour, 6 hours, 24 hours), and on Days 1, 7, 14, 21, 28, 42, 56, and 84 post-dose
Volume of Distribution (Vz) of Belimumab
Blood samples were collected at the indicated time points to calculate Vz of belimumab.
Time frame: Day 0 (pre-dose, 5 minutes, 1 hour, 6 hours, 24 hours), and on Days 1, 7, 14, 21, 28, 42, 56, and 84 post-dose
Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE)
AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. For marketed medicinal products, this also includes failure to produce expected benefits (i.e., lack of efficacy), abuse or misuse. SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect or is medically significant, or associated with liver injury and impaired liver function.
Time frame: Up to Day 84
Change From Baseline to Day 84 in Vital Signs- Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
Vital signs included SBP and DBP. SBP and DBP were measured with the participant in the sitting position. Baseline was pre-dose on Day 0. Change from Baseline was defined as the post-Baseline value minus the Baseline value.
Time frame: Baseline (pre-dose on Day 0) to Day 84
Change From Baseline to Day 84 in Vital Sign- Pulse Rate
Vital signs included pulse rate. Baseline was pre-dose on Day 0. Change from Baseline was defined as the post-Baseline value minus the Baseline value.
Time frame: Baseline (pre-dose on Day 0) to Day 84
Change From Baseline to Day 84 in Vital Sign- Temperature
Vital signs included temperature. Baseline was pre-dose on Day 0. Change from Baseline was defined as the post-Baseline value minus the Baseline value.
Time frame: Baseline (pre-dose on Day 0) to Day 84
Number of Participants With Abnormal-clinically Significant 12-lead Electrocardiogram (ECG) Findings
ECG parameters included heart rate, PR interval, QRS interval, QT interval and corrected QT (QTc) interval. Number of participants with abnormal-clinically significant 12-lead ECG findings are presented.
Time frame: Up to Day 84
Change From Baseline to Day 84 in Clinical Chemistry Parameters- Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase
Clinical chemistry parameters included ALT, ALP, AST, GGT and lactate dehydrogenase. Baseline was pre-dose on Day 0. Change from Baseline was defined as the post-Baseline value minus the Baseline value.
Time frame: Baseline (pre-dose on Day 0) to Day 84
Change From Baseline to Day 84 in Clinical Chemistry Parameters- Albumin and Protein
Clinical chemistry parameters included albumin and protein. Baseline was pre-dose on Day 0. Change from Baseline was defined as the post-Baseline value minus the Baseline value.
Time frame: Baseline (pre-dose on Day 0) to Day 84
Change From Baseline to Day 84 in Clinical Chemistry Parameters- Bilirubin, Creatinine, Direct Bilirubin, Indirect Bilirubin and Urate
Clinical chemistry parameters included bilirubin, creatinine, direct bilirubin, indirect bilirubin and urate. Baseline was pre-dose on Day 0. Change from Baseline was defined as the post-Baseline value minus the Baseline value.
Time frame: Baseline (pre-dose on Day 0) to Day 84
Change From Baseline to Day 84 in Clinical Chemistry Parameters- Calcium, Calcium Corrected, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium, Sodium, Urea and Glucose
Clinical chemistry parameters included calcium, calcium corrected, carbon dioxide, chloride, magnesium, phosphate, potassium, sodium, urea and glucose. Baseline was pre-dose on Day 0. Change from Baseline was defined as the post-Baseline value minus the Baseline value.
Time frame: Baseline (pre-dose on Day 0) to Day 84
Change From Baseline to Day 84 in Hematology Laboratory Parameters- Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils and Platelets
Hematology parameters included basophils, eosinophils, leukocytes, lymphocytes, monocytes, neutrophils and platelets. Baseline was pre-dose on Day 0. Change from Baseline was defined as the post-Baseline value minus the Baseline value.
Time frame: Baseline (pre-dose on Day 0) to Day 84
Change From Baseline to Day 84 in Hematology Parameter- Erythrocytes
Hematology parameter included erythrocytes. Baseline was pre-dose on Day 0. Change from Baseline was defined as the post-Baseline value minus the Baseline value.
Time frame: Baseline (pre-dose on Day 0) to Day 84
Change From Baseline to Day 84 in Hematology Parameter- Hematocrit
Hematology parameter included hematocrit. Baseline was pre-dose on Day 0. Change from Baseline was defined as the post-Baseline value minus the Baseline value.
Time frame: Baseline (pre-dose on Day 0) to Day 84
Change From Baseline to Day 84 in Hematology Parameter- Hemoglobin
Hematology parameter included hemoglobin. Baseline was pre-dose on Day 0. Change from Baseline was defined as the post-Baseline value minus the Baseline value.
Time frame: Baseline (pre-dose on Day 0) to Day 84
Number of Participants With Positive Urinalysis Dipstick Results
Urinalysis was done by the dipstick method to detect the presence of protein, glucose, ketones and occult blood in urine. The dipstick test gives results in a semi-quantitative manner, and results for urinalysis parameter of urine occult blood, urine protein and urine ketones can be read as negative, Trace, 1+, 2+, 3+ and 4+, indicating proportional concentrations in the urine sample; results for urinalysis parameter of urine glucose can be read as negative, Trace, 1+ or 1/4 gram per Liter (g/L), 2+ or 1/2 g/L, 3+ or 1 g/L and 4+ indicating proportional concentrations in the urine sample. \*a indicates two participants did not take the urinalysis test at Day 14 on scheduled date but took an unscheduled sample at the next visit (Day 21) and \*b indicates one participant did not take the urinalysis test at Day 28 on scheduled date but took an unscheduled sample at the next visit (Day 42). Only those participants with positive results have been presented.
Time frame: Day 0 (24 hours), Day 14, Day 21, Day 28, Day 42, Day 56 and Day 84
Percent Change From Baseline to Day 84 in B Cell Subsets (Cluster of Differentiation [CD]19 and CD 20+) for Pharmacodynamic Assessment
Immunoglobulin B cell subsets included CD19 and CD 20+. Baseline was pre-dose on Day 0. Change from Baseline was defined as the post-Baseline value minus the Baseline value. Percent change from Baseline was calculated as 100 multiplied by \[(Post-Baseline Visit Value minus Baseline) / Baseline\]. Pharmacodynamic population comprised of participants who received the study medication and for whom pharmacodynamic data was available.
Time frame: Baseline (pre-dose on Day 0) to Day 84
Percent Change From Baseline to Day 84 in B Cell Subsets (CD20+/27+ Memory and CD20+/27-naïve) for the Pharmacodynamic Assessment
Immunoglobulin B cell subset included CD20+/27+ memory and CD20+/27-naïve. Baseline was pre-dose on Day 0. Change from Baseline was defined as the post-Baseline value minus the Baseline value. Percent change from Baseline was calculated as 100 multiplied by \[(Post-Baseline Visit Value minus Baseline) / Baseline\].
Time frame: Baseline (pre-dose on Day 0) to Day 84
Percent Change From Baseline to Day 84 in Immunoglobulins B Cell Subset (Normalized [Norm] CD19+/27BRIGHT[Br]/38Br SLE Subset, Norm CD20+/138+Plasmacytoid, Norm CD20+/69+Activated and Norm CD20-/CD138+Plasma Cell) for Pharmacodynamic Assessment
Immunoglobulin B cell subset inlcuded Norm CD19+/27Br/38Br SLE subset, Norm CD20+/138+plasmacytoid, Norm CD20+/69+activated and Norm CD20-/CD138+plasma cell. Baseline was pre-dose on Day 0. Change from Baseline was defined as the post-Baseline value minus the Baseline value. Percent change from Baseline was calculated as 100 multiplied by \[(Post-Baseline Visit Value minus Baseline) / Baseline\].
Time frame: Baseline (pre-dose on Day 0) to Day 84
A total of 20 participants with Systemic Lupus Erythematosus (SLE) were enrolled. The study was conducted at 2 centers in China from 23-Jan-2017 to 08-Sep-2017.
| Milestone | Belimumab 10 mg/kg |
|---|---|
| Started | 20 |
| Completed | 20 |
| Not completed | 0 |
Blood samples were collected at the indicated timepoints to calculate Cmax of belimumab.
| Micrograms per milliliter | Belimumab 10 mg/kg |
|---|---|
| Maximum Observed Concentration (Cmax) of Belimumab | 221.3532 ± 12.8405 |
Blood samples were collected at the indicated timepoints to calculate AUC (0 to t) and AUC (0 to inf) of belimumab.
| Day*micrograms/milliliter | Belimumab 10 mg/kg |
|---|---|
| AUC(0 to t) | 2395.3030 ± 23.2924 |
| AUC(0 to inf) | 2461.8013 ± 24.7125 |
Blood samples were collected at the indicated time points to calculate t1/2 of belimumab.
| Days | Belimumab 10 mg/kg |
|---|---|
| Terminal Phase Half-life (t1/2) of Belimumab | 14.6283 ± 35.4339 |
Blood samples were collected at the indicated time points to calculate lambda z of belimumab.
| 1/day | Belimumab 10 mg/kg |
|---|---|
| Terminal Phase Rate Constant (Lambda z) of Belimumab | 0.0474 ± 35.4339 |
Blood samples were collected at the indicated time points to calculate CL of belimumab.
| (Milliliters/day)/kilogram | Belimumab 10 mg/kg |
|---|---|
| Systemic Clearance (CL) of Belimumab | 4.0621 ± 24.7125 |
Blood samples were collected at the indicated time points to calculate Vz of belimumab.
| Milliliters/kilogram | Belimumab 10 mg/kg |
|---|---|
| Volume of Distribution (Vz) of Belimumab | 85.7265 ± 21.6704 |
AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. For marketed medicinal products, this also includes failure to produce expected benefits (i.e., lack of efficacy), abuse or misuse. SAE is any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect or is medically significant, or associated with liver injury and impaired liver function.
| Participants | Belimumab 10 mg/kg |
|---|---|
| AE | 12 |
| SAE | 1 |
Vital signs included SBP and DBP. SBP and DBP were measured with the participant in the sitting position. Baseline was pre-dose on Day 0. Change from Baseline was defined as the post-Baseline value minus the Baseline value.
| Millimeters of mercury | Belimumab 10 mg/kg |
|---|---|
| DBP: Day 0 (5 minutes post-dose) | -0.5 ± 6.35 |
| DBP: Day 0 (1 hour post-dose) | -1.5 ± 12.51 |
| DBP: Day 0 (6 hours post-dose) | -2.1 ± 8.57 |
| DBP: Day 0 (24 hours post-dose) | -0.1 ± 7.95 |
| DBP: Day 1 | 2.2 ± 8.37 |
| DBP: Day 7 | 1.1 ± 7.91 |
| DBP: Day 14 | 0.5 ± 8.65 |
| DBP: Day 21 | 0.1 ± 6.91 |
| DBP: Day 28 | 0.2 ± 8.86 |
| DBP: Day 42 | -3.2 ± 7.99 |
| DBP: Day 56 | -0.8 ± 8.85 |
| DBP: Day 84 | -0.6 ± 11.06 |
| SBP: Day 0 (5 minutes post-dose) | 0.8 ± 9.92 |
| SBP: Day 0 (1 hour post-dose) | -2.5 ± 11.44 |
| SBP: Day 0 (6 hours post-dose) | -4.5 ± 12.15 |
| SBP: Day 0 (24 hours post-dose) | -3.7 ± 11.76 |
| SBP: Day 1 | -2.4 ± 10.92 |
| SBP: Day 7 | 0.7 ± 10.65 |
| SBP: Day 14 | -1.0 ± 12.09 |
| SBP: Day 21 | -4.4 ± 12.05 |
| SBP: Day 28 | -1.5 ± 14.01 |
| SBP: Day 42 | -7.4 ± 9.26 |
| SBP: Day 56 | -4.0 ± 11.14 |
| SBP: Day 84 | -7.4 ± 14.91 |
Vital signs included pulse rate. Baseline was pre-dose on Day 0. Change from Baseline was defined as the post-Baseline value minus the Baseline value.
| Beats per minute | Belimumab 10 mg/kg |
|---|---|
| Day 0 (5 minutes post-dose) | -1.2 ± 11.13 |
| Day 0 (1 hour post-dose) | -1.6 ± 8.43 |
| Day 0 (6 hours post-dose) | 2.6 ± 12.14 |
| Day 0 (24 hours post-dose) | 2.3 ± 11.08 |
| Day 1 | 5.7 ± 11.09 |
| Day 7 | 4.7 ± 11.82 |
| Day 14 | 6.9 ± 10.55 |
| Day 21 | 5.0 ± 8.90 |
| Day 28 | 7.6 ± 10.02 |
| Day 42 | 8.3 ± 12.06 |
| Day 56 | 4.1 ± 10.80 |
| Day 84 | 3.2 ± 14.21 |
Vital signs included temperature. Baseline was pre-dose on Day 0. Change from Baseline was defined as the post-Baseline value minus the Baseline value.
| Celsius | Belimumab 10 mg/kg |
|---|---|
| Day 0 (5 minutes post-dose) | 0.21 ± 0.485 |
| Day 0 (1 hour post-dose) | 0.17 ± 0.473 |
| Day 0 (6 hours post-dose) | 0.20 ± 0.552 |
| Day 0 (24 hours post-dose) | 0.40 ± 0.617 |
| Day 1 | 0.24 ± 0.486 |
| Day 7 | 0.40 ± 0.793 |
| Day 14 | 0.40 ± 0.504 |
| Day 21 | 0.41 ± 0.454 |
| Day 28 | 0.37 ± 0.457 |
| Day 42 | 0.53 ± 0.595 |
| Day 56 | 0.52 ± 0.473 |
| Day 84 | 0.38 ± 0.434 |
ECG parameters included heart rate, PR interval, QRS interval, QT interval and corrected QT (QTc) interval. Number of participants with abnormal-clinically significant 12-lead ECG findings are presented.
| Participants | Belimumab 10 mg/kg |
|---|---|
| Number of Participants With Abnormal-clinically Significant 12-lead Electrocardiogram (ECG) Findings | 0 |
Clinical chemistry parameters included ALT, ALP, AST, GGT and lactate dehydrogenase. Baseline was pre-dose on Day 0. Change from Baseline was defined as the post-Baseline value minus the Baseline value.
| International units per Liter (IU/L) | Belimumab 10 mg/kg |
|---|---|
| ALT: Day 0 (24 hours) | -1.6 ± 3.46 |
| ALT: Day 14 | -1.3 ± 11.93 |
| ALT: Day 28 | -3.2 ± 12.34 |
| ALT: Day 56 | -5.0 ± 12.18 |
| ALT: Day 84 | -5.5 ± 11.84 |
| ALP: Day 0 (24 hours) | -3.9 ± 3.56 |
| ALP: Day 14 | -5.6 ± 10.72 |
| ALP: Day 28 | -3.4 ± 8.80 |
| ALP: Day 56 | -7.2 ± 9.26 |
| ALP: Day 84 | -7.3 ± 11.80 |
| AST: Day 0 (24 hours) | -1.9 ± 2.48 |
| AST: Day 14 | -1.8 ± 8.58 |
| AST: Day 28 | -2.6 ± 8.46 |
| AST: Day 56 | -2.8 ± 6.15 |
| AST: Day 84 | -3.6 ± 6.86 |
| GGT: Day 0 (24 hours) | -1.5 ± 2.33 |
| GGT: Day 14 | -0.5 ± 7.34 |
| GGT: Day 28 | 0.5 ± 7.22 |
| GGT: Day 56 | -4.1 ± 6.08 |
| GGT: Day 84 | -3.3 ± 8.44 |
| Lactate dehydrogenase: Day 0 (24 hours) | -8.1 ± 10.56 |
| Lactate dehydrogenase: Day 14 | -3.2 ± 18.88 |
| Lactate dehydrogenase: Day 28 | -1.4 ± 22.30 |
| Lactate dehydrogenase: Day 56 | 1.3 ± 24.30 |
| Lactate dehydrogenase: Day 84 | 1.5 ± 20.68 |
Clinical chemistry parameters included albumin and protein. Baseline was pre-dose on Day 0. Change from Baseline was defined as the post-Baseline value minus the Baseline value.
| Grams per liter (g/L) | Belimumab 10 mg/kg |
|---|---|
| Albumin: Day 0 (24 hours) | -1.4 ± 1.88 |
| Albumin: Day 14 | -1.1 ± 3.08 |
| Albumin: Day 28 | -0.6 ± 2.68 |
| Albumin: Day 56 | -0.5 ± 3.14 |
| Albumin: Day 84 | -0.6 ± 3.10 |
| Protein: Day 0 (24 hours) | -3.8 ± 2.67 |
| Protein: Day 14 | -3.2 ± 5.12 |
| Protein: Day 28 | -3.3 ± 4.47 |
| Protein: Day 56 | -3.8 ± 5.41 |
| Protein: Day 84 | -3.8 ± 4.23 |
Clinical chemistry parameters included bilirubin, creatinine, direct bilirubin, indirect bilirubin and urate. Baseline was pre-dose on Day 0. Change from Baseline was defined as the post-Baseline value minus the Baseline value.
| Micromoles per Liter (µmol/L) | Belimumab 10 mg/kg |
|---|---|
| Bilirubin: Day 0 (24 hours) | -2.8 ± 3.07 |
| Bilirubin: Day 14 | -2.4 ± 4.48 |
| Bilirubin: Day 28 | -3.4 ± 4.55 |
| Bilirubin: Day 56 | -3.2 ± 5.17 |
| Bilirubin: Day 84 | -2.1 ± 4.83 |
| Creatinine: Day 0 (24 hours) | -0.18 ± 4.479 |
| Creatinine: Day 14 | -0.80 ± 5.502 |
| Creatinine: Day 28 | -0.43 ± 6.698 |
| Creatinine: Day 56 | -0.25 ± 5.962 |
| Creatinine: Day 84 | -0.18 ± 6.062 |
| Direct bilirubin: Day 0 (24 hours) | -0.4 ± 1.05 |
| Direct bilirubin: Day 14 | 0.1 ± 1.37 |
| Direct bilirubin: Day 28 | -0.6 ± 1.14 |
| Direct bilirubin: Day 56 | -0.6 ± 1.47 |
| Direct bilirubin: Day 84 | -0.2 ± 1.28 |
| Indirect bilirubin: Day 0 (24 hours) | -2.4 ± 2.87 |
| Indirect bilirubin: Day 14 | -2.5 ± 4.10 |
| Indirect bilirubin: Day 28 | -2.8 ± 4.12 |
| Indirect bilirubin: Day 56 | -2.6 ± 4.26 |
| Indirect bilirubin: Day 84 | -1.9 ± 4.79 |
| Urate: Day 0 (24 hours) | -14.5 ± 21.88 |
| Urate: Day 14 | -10.5 ± 34.41 |
| Urate: Day 28 | -13.5 ± 47.49 |
| Urate: Day 56 | -2.5 ± 49.93 |
| Urate: Day 84 | -7.5 ± 50.67 |
Clinical chemistry parameters included calcium, calcium corrected, carbon dioxide, chloride, magnesium, phosphate, potassium, sodium, urea and glucose. Baseline was pre-dose on Day 0. Change from Baseline was defined as the post-Baseline value minus the Baseline value.
| Millimoles per Liter (mmol/L) | Belimumab 10 mg/kg |
|---|---|
| Calcium: Day 0 (24 hours) | -0.040 ± 0.0599 |
| Calcium: Day 14 | -0.020 ± 0.1049 |
| Calcium: Day 28 | 0.004 ± 0.0848 |
| Calcium: Day 56 | -0.020 ± 0.1054 |
| Calcium: Day 84 | -0.027 ± 0.0909 |
| Calcium Corrected: Day 0 (24 hours) | -0.010 ± 0.0466 |
| Calcium Corrected: Day 14 | 0.003 ± 0.0663 |
| Calcium Corrected: Day 28 | 0.017 ± 0.0578 |
| Calcium Corrected: Day 56 | -0.007 ± 0.0694 |
| Calcium Corrected: Day 84 | -0.016 ± 0.0501 |
| Carbon dioxide: Day 0 (24 hours) | -0.3 ± 1.86 |
| Carbon dioxide: Day 14 | -0.2 ± 2.32 |
| Carbon dioxide: Day 28 | 0.1 ± 2.09 |
| Carbon dioxide: Day 56 | -0.1 ± 2.33 |
| Carbon dioxide: Day 84 | -0.2 ± 1.64 |
| Chloride: Day 0 (24 hours) | 1.3 ± 2.12 |
| Chloride: Day 14 | 0.3 ± 2.05 |
| Chloride: Day 28 | 0.4 ± 1.53 |
| Chloride: Day 56 | 1.3 ± 1.63 |
| Chloride: Day 84 | 1.2 ± 1.74 |
| Magnesium: Day 0 (24 hours) | -0.044 ± 0.0564 |
| Magnesium: Day 14 | -0.046 ± 0.0623 |
| Magnesium: Day 28 | -0.049 ± 0.0709 |
| Magnesium: Day 56 | -0.029 ± 0.0750 |
| Magnesium: Day 84 | -0.034 ± 0.0751 |
| Phosphate: Day 0 (24 hours) | -0.085 ± 0.1299 |
| Phosphate: Day 14 | -0.132 ± 0.2104 |
| Phosphate: Day 28 | -0.135 ± 0.2201 |
| Phosphate: Day 56 | -0.140 ± 0.2037 |
| Phosphate: Day 84 | -0.152 ± 0.1509 |
| Potassium: Day 0 (24 hours) | -0.10 ± 0.333 |
| Potassium: Day 14 | -0.04 ± 0.355 |
| Potassium: Day 28 | -0.11 ± 0.335 |
| Potassium: Day 56 | -0.13 ± 0.370 |
| Potassium: Day 84 | -0.29 ± 0.356 |
| Sodium: Day 0 (24 hours) | 0.1 ± 2.24 |
| Sodium: Day 14 | 0.3 ± 1.59 |
| Sodium: Day 28 | 0.1 ± 1.28 |
| Sodium: Day 56 | 0.8 ± 1.68 |
| Sodium: Day 84 | 0.8 ± 1.67 |
| Urea: Day 0 (24 hours) | 0.20 ± 0.733 |
| Urea: Day 14 | 0.38 ± 1.122 |
| Urea: Day 28 | 0.10 ± 1.382 |
| Urea: Day 56 | -0.13 ± 0.793 |
| Urea: Day 84 | -0.20 ± 1.152 |
| Glucose: Day 0 (24 hours) | 0.98 ± 3.248 |
| Glucose: Day 14 | 1.66 ± 2.094 |
| Glucose: Day 28 | 0.33 ± 2.230 |
| Glucose: Day 56 | 0.19 ± 2.093 |
| Glucose: Day 84 | 0.57 ± 2.749 |
Hematology parameters included basophils, eosinophils, leukocytes, lymphocytes, monocytes, neutrophils and platelets. Baseline was pre-dose on Day 0. Change from Baseline was defined as the post-Baseline value minus the Baseline value.
| 10^9 cells/Liter | Belimumab 10 mg/kg |
|---|---|
| Basophils: Day 0 (24 hours) | -0.006 ± 0.0110 |
| Basophils: Day 14 | -0.011 ± 0.0176 |
| Basophils: Day 28 | -0.013 ± 0.0186 |
| Basophils: Day 56 | -0.008 ± 0.0162 |
| Basophils: Day 84 | -0.005 ± 0.0115 |
| Eosinophils: Day 0 (24 hours) | -0.019 ± 0.0506 |
| Eosinophils: Day 14 | -0.024 ± 0.0564 |
| Eosinophils: Day 28 | -0.006 ± 0.0535 |
| Eosinophils: Day 56 | -0.022 ± 0.0595 |
| Eosinophils: Day 84 | -0.028 ± 0.0670 |
| Leukocytes: Day 0 (24 hours) | 0.29 ± 0.899 |
| Leukocytes: Day 14 | 0.09 ± 1.403 |
| Leukocytes: Day 28 | 1.00 ± 1.589 |
| Leukocytes: Day 56 | 0.54 ± 1.337 |
| Leukocytes: Day 84 | -0.04 ± 1.754 |
| Lymphocytes: Day 0 (24 hours) | -0.068 ± 0.5214 |
| Lymphocytes: Day 14 | -0.180 ± 0.6718 |
| Lymphocytes: Day 28 | -0.364 ± 0.6746 |
| Lymphocytes: Day 56 | -0.287 ± 0.5812 |
| Lymphocytes: Day 84 | -0.257 ± 0.5697 |
| Monocytes: Day 0 (24 hours) | 0.005 ± 0.1300 |
| Monocytes: Day 14 | -0.025 ± 0.1575 |
| Monocytes: Day 28 | -0.077 ± 0.2568 |
| Monocytes: Day 56 | -0.076 ± 0.1574 |
| Monocytes: Day 84 | -0.059 ± 0.1878 |
| Neutrophils: Day 0 (24 hours) | 0.389 ± 0.9085 |
| Neutrophils: Day 14 | 0.332 ± 1.8713 |
| Neutrophils: Day 28 | 1.464 ± 1.9750 |
| Neutrophils: Day 56 | 0.932 ± 1.3943 |
| Neutrophils: Day 84 | 0.305 ± 1.7297 |
| Platelets: Day 0 (24 hours) | -6.3 ± 12.68 |
| Platelets: Day 14 | 2.1 ± 26.11 |
| Platelets: Day 28 | 10.0 ± 30.14 |
| Platelets: Day 56 | 1.0 ± 20.84 |
| Platelets: Day 84 | -4.1 ± 29.04 |
Hematology parameter included erythrocytes. Baseline was pre-dose on Day 0. Change from Baseline was defined as the post-Baseline value minus the Baseline value.
| 10^12 cells/Liter | Belimumab 10 mg/kg |
|---|---|
| Day 0 (24 hours) | -0.12 ± 0.158 |
| Day 14 | -0.19 ± 0.246 |
| Day 28 | -0.13 ± 0.205 |
| Day 56 | -0.16 ± 0.239 |
| Day 84 | -0.18 ± 0.282 |
Hematology parameter included hematocrit. Baseline was pre-dose on Day 0. Change from Baseline was defined as the post-Baseline value minus the Baseline value.
| Proportion of red blood cells in blood | Belimumab 10 mg/kg |
|---|---|
| Day 0 (24 hours) | -0.0112 ± 0.0170 |
| Day 14 | -0.0176 ± 0.0272 |
| Day 28 | 0.0006 ± 0.0310 |
| Day 56 | -0.0060 ± 0.0226 |
| Day 84 | -0.0126 ± 0.0313 |
Hematology parameter included hemoglobin. Baseline was pre-dose on Day 0. Change from Baseline was defined as the post-Baseline value minus the Baseline value.
| Grams per Liter (g/L) | Belimumab 10 mg/kg |
|---|---|
| Day 0 (24 hours) | -3.7 ± 4.83 |
| Day 14 | -5.0 ± 7.14 |
| Day 28 | -4.0 ± 5.55 |
| Day 56 | -5.0 ± 8.04 |
| Day 84 | -5.7 ± 10.11 |
Urinalysis was done by the dipstick method to detect the presence of protein, glucose, ketones and occult blood in urine. The dipstick test gives results in a semi-quantitative manner, and results for urinalysis parameter of urine occult blood, urine protein and urine ketones can be read as negative, Trace, 1+, 2+, 3+ and 4+, indicating proportional concentrations in the urine sample; results for urinalysis parameter of urine glucose can be read as negative, Trace, 1+ or 1/4 gram per Liter (g/L), 2+ or 1/2 g/L, 3+ or 1 g/L and 4+ indicating proportional concentrations in the urine sample. \*a indicates two participants did not take the urinalysis test at Day 14 on scheduled date but took an unscheduled sample at the next visit (Day 21) and \*b indicates one participant did not take the urinalysis test at Day 28 on scheduled date but took an unscheduled sample at the next visit (Day 42). Only those participants with positive results have been presented.
| Participants | Belimumab 10 mg/kg |
|---|---|
| Glucose: Day 14, 1+ or 1/4 g/L | 1 |
| Glucose: Day 14, 2+ or 1/2 g/L | 1 |
| Glucose: Day 14, Trace | 1 |
| Glucose: Day 28, 1+ or 1/4 g/L | 1 |
| Glucose: Day 56, 1+ or 1/4 g/L | 1 |
| Occult Blood: Day 0 (24 hours), Trace | 5 |
| Occult Blood: Day 0 (24 hours), 1+ | 1 |
| Occult Blood: Day 0 (24 hours), 3+ | 1 |
| Occult Blood: Day 14, Trace | 4 |
| Occult Blood: Day 14, 1+ | 2 |
| Occult Blood: Day 14, 2+ | 1 |
| Occult Blood: Day 21*a, Trace | 1 |
| Occult Blood: Day 28, Trace | 6 |
| Occult Blood: Day 28, 2+ | 2 |
| Occult Blood: Day 56, Trace | 5 |
| Occult Blood: Day 56, 1+ | 2 |
| Occult Blood: Day 56, 2+ | 2 |
| Occult Blood: Day 84, Trace | 1 |
| Occult Blood: Day 84, 1+ | 3 |
| Occult Blood: Day 84, 2+ | 1 |
| Protein: Day 0 (24 hours), 2+ | 1 |
| Protein: Day 14, Trace | 3 |
| Protein: Day 14, 1+ | 1 |
| Protein: Day 28, 2+ | 1 |
| Protein: Day 42*b, Trace | 1 |
| Protein: Day 56, Trace | 2 |
| Protein: Day 84, Trace | 3 |
| Protein: Day 84, 2+ | 1 |
Immunoglobulin B cell subsets included CD19 and CD 20+. Baseline was pre-dose on Day 0. Change from Baseline was defined as the post-Baseline value minus the Baseline value. Percent change from Baseline was calculated as 100 multiplied by \[(Post-Baseline Visit Value minus Baseline) / Baseline\]. Pharmacodynamic population comprised of participants who received the study medication and for whom pharmacodynamic data was available.
| Percent change | Belimumab 10 mg/kg |
|---|---|
| CD19: Day 14, n=20 | 26.6444 ± 78.2275 |
| CD19: Day 28, n=20 | -4.1141 ± 49.0574 |
| CD19: Day 42, n=19 | -12.6852 ± 46.6312 |
| CD19: Day 56, n=20 | -20.4908 ± 44.2536 |
| CD19: Day 84, n=20 | -27.0912 ± 49.5965 |
| CD20+: Day 14, n=20 | 35.3407 ± 100.7209 |
| CD20+: Day 28, n=20 | 0.3444 ± 54.1435 |
| CD20+: Day 42, n=19 | -8.6327 ± 52.1804 |
| CD20+: Day 56, n=20 | -20.6313 ± 42.8535 |
| CD20+: Day 84, n=20 | -23.7421 ± 62.8031 |
Immunoglobulin B cell subset included CD20+/27+ memory and CD20+/27-naïve. Baseline was pre-dose on Day 0. Change from Baseline was defined as the post-Baseline value minus the Baseline value. Percent change from Baseline was calculated as 100 multiplied by \[(Post-Baseline Visit Value minus Baseline) / Baseline\].
| Percent change | Belimumab 10 mg/kg |
|---|---|
| CD20+/27+ memory: Day 14, n=20 | 186.4701 ± 199.5187 |
| CD20+/27+ memory: Day 28, n=20 | 118.1433 ± 135.2351 |
| CD20+/27+ memory: Day 42, n=19 | 91.2965 ± 125.1803 |
| CD20+/27+ memory: Day 56, n=20 | 135.8139 ± 167.0084 |
| CD20+/27+ memory: Day 84, n=20 | 70.6332 ± 108.1058 |
| CD20+/27-naïve: Day 14, n=20 | 4.0530 ± 61.8752 |
| CD20+/27-naïve: Day 28, n=20 | -15.9190 ± 48.8363 |
| CD20+/27-naïve: Day 42, n=19 | -17.0090 ± 61.5514 |
| CD20+/27-naïve: Day 56, n=20 | -40.2078 ± 37.1774 |
| CD20+/27-naïve: Day 84, n=20 | -42.6608 ± 43.8690 |
Immunoglobulin B cell subset inlcuded Norm CD19+/27Br/38Br SLE subset, Norm CD20+/138+plasmacytoid, Norm CD20+/69+activated and Norm CD20-/CD138+plasma cell. Baseline was pre-dose on Day 0. Change from Baseline was defined as the post-Baseline value minus the Baseline value. Percent change from Baseline was calculated as 100 multiplied by \[(Post-Baseline Visit Value minus Baseline) / Baseline\].
| Percent change | Belimumab 10 mg/kg |
|---|---|
| Norm CD19+/27Br/38Br SLE subset: Day 14, n=20 | 5.3271 ± 85.7472 |
| Norm CD19+/27Br/38Br SLE subset: Day 28, n=20 | -4.4623 ± 91.3321 |
| Norm CD19+/27Br/38Br SLE subset: Day 42, n=19 | 17.2492 ± 132.2146 |
| Norm CD19+/27Br/38Br SLE subset: Day 56, n=20 | 48.1481 ± 148.1877 |
| Norm CD19+/27Br/38Br SLE subset: Day 84, n=20 | 24.9838 ± 118.1567 |
| Norm CD20+/138+plasmacytoid: Day 14, n=19 | 200.6464 ± 702.0072 |
| Norm CD20+/138+plasmacytoid: Day 28, n=19 | 255.8559 ± 1010.9303 |
| Norm CD20+/138+plasmacytoid: Day 42, n=18 | 2.7891 ± 145.0411 |
| Norm CD20+/138+plasmacytoid: Day 56, n=19 | 20.1061 ± 220.7714 |
| Norm CD20+/138+plasmacytoid: Day 84, n=19 | -44.0743 ± 65.0501 |
| Norm CD20+/69+activated: Day 14, n=19 | -0.9711 ± 196.9956 |
| Norm CD20+/69+activated: Day 28, n=19 | 106.5032 ± 379.9580 |
| Norm CD20+/69+activated: Day 42, n=18 | 9.8018 ± 138.7995 |
| Norm CD20+/69+activated: Day 56, n=19 | 15.6984 ± 132.7055 |
| Norm CD20+/69+activated: Day 84, n=19 | -18.3523 ± 120.1047 |
| Norm CD20-/CD138+plasma cells: Day 14, n=20 | 24.3489 ± 151.0876 |
| Norm CD20-/CD138+plasma cells: Day 28, n=20 | 21.4906 ± 180.2169 |
| Norm CD20-/CD138+plasma cells: Day 42, n=19 | -6.6055 ± 129.1377 |
| Norm CD20-/CD138+plasma cells: Day 56, n=20 | 3.0692 ± 175.5913 |
| Norm CD20-/CD138+plasma cells: Day 84, n=20 | -51.0462 ± 38.0848 |
Collected over Up to Day 84. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Belimumab 10 mg/kg | 0/20 (0%) | 1/20 (5%) | 11/20 (55%) |
| Event | Belimumab 10 mg/kg |
|---|---|
| NeutropeniaBlood and lymphatic system disorders | 1/20 |
| Upper respiratory tract infectionInfections and infestations | 1/20 |
| Event | Belimumab 10 mg/kg |
|---|---|
| Upper respiratory tract infectionInfections and infestations | 4/20 |
| HyperglycaemiaMetabolism and nutrition disorders | 2/20 |
| GingivitisInfections and infestations | 1/20 |
| PharyngitisInfections and infestations | 1/20 |
| AnaemiaBlood and lymphatic system disorders | 1/20 |
| HypokalaemiaMetabolism and nutrition disorders | 1/20 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 1/20 |
| Productive coughRespiratory, thoracic and mediastinal disorders | 1/20 |
| Bone infarctionMusculoskeletal and connective tissue disorders | 1/20 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 1/20 |
Safety Population which comprised of all the participants who received at least one dose of study medication.
| Age, Continuous(Years) | Belimumab 10 mg/kg |
|---|---|
| Mean | 37.4 ± 14.07 |
| Sex: Female, Male(Participants) | Belimumab 10 mg/kg |
|---|---|
| Female | 16 |
| Male | 4 |
| Race/Ethnicity, Customized(Participants) | Belimumab 10 mg/kg |
|---|---|
| Asian - East Asian Heritage | 20 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: IPD is available via the Clinical Study Data Request site (click on the link provided below)
Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Data sharing details ↗ · clinicalstudydatarequest.com
Ran from Jan 2017 to primary completion in Sep 2017, 7 months.
Results were first posted in Nov 2018, 1 year 2 months after primary completion.
Of 108 industry-sponsored phase 1 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 35. This study's 7 months is below that.
Counting every sponsor, half of 147 studies reached it within 28 months; a quarter within 16 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Belimumab
Lupus Erythematosus, Systemic →